Actively Recruiting
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
Led by Shandong Suncadia Medicine Co., Ltd. · Updated on 2025-12-18
206
Participants Needed
2
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.
CONDITIONS
Official Title
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with unresectable locally advanced or metastatic solid tumors confirmed by histology or cytology who have relapsed or progressed after standard treatment, or have no standard treatment options, or do not apply standard treatment at this stage
- Age 18 to 75 years old
- At least one measurable lesion per RECIST v1.1 criteria
- ECOG PS score of 0 or 1
You will not qualify if you...
- History of other malignancies within the past 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix
- Previous anti-tumor therapy adverse reactions not recovered to NCI-CTCAE v5.0 grade 1 or less
- Severe cardiovascular and cerebrovascular diseases
- Severe infection within 4 weeks prior to the first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210008
Actively Recruiting
2
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
X
Xin Xu
CONTACT
Z
Zhiye Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here